Profs Urge Full Fed. Circ. To Review 'Startling' Novartis Ruling

By Britain Eakin (August 5, 2022, 4:57 PM EDT) -- Two groups of law professors have urged the full Federal Circuit to review a case in which a split panel initially sided with Novartis in January and upheld its patent on multibillion-dollar multiple sclerosis drug Gilenya, but then invalidated it after a different judge joined the panel....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!